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cases with this procedure, we wonder
whether the results have always been good.
Although we have some points to be
clarified, we again congratulate Fukuda
and associates1 on their successful results
in this complicated case. In our opinion,
transapical aortic cannulation should be the
last alternative. No one can predict the re-
sults of this procedure.
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Reply to the Editor:
We thank Terada and Nakamura for their
comments regarding our work.1 Transapical
aortic cannulation was originally described in
the 1970s. However, it has been unpopular
because of similar comments by the critics.
Originally this method was used in sur-
gery for congenital heart disease or mitral
valvular disease.2 The main reason for the
use of transapical aortic cannulation today
is for surgery on diseased aorta without
intracardiac abnormality. Thus the indica-
tion for this method today is different from
that during the 1970s.
We have used transapical aortic cannu-
lation in 4 patients (2 in median sternotomy
and 2 in left thoracotomy) without any se-
rious adverse effects. Although the volume
of our experience is small, we would like to
comment on it. With respect to hypoten-
sion during elevation of the apex, its dura-
tion was quite short, and the blood pressure
recovered as soon as the apex was lowered
into normal position. Although elevation of
the apex of a beating heart can be an un-
comfortable procedure for a cardiac sur-
geon, we were accustomed to this proce-
dure from our recent experience with off-
pump coronary artery bypass grafting.
In addition, hypotension during insertion
of the cannula was advantageous to reduce
the amount of bleeding during puncture of
the apex. To prevent devastating hemorrhage
during cannulation and to avoid dislocation
of the cannula, purse-string suture with Da-
cron polyester felt was placed at the apex and
preliminary venous cannulation was per-
formed. In 2 patients the femoral artery was
cannulated as an accessory perfusion site to
the lower extremities. We evaluated aortic
regurgitation during aortic perfusion, and it
was mild on duplex scanning. Intraoperative
findings revealed a competent aortic valve
with aortic cannula positioning at the center
of the aortic orifice. Although clamping of
the ascending aorta was impossible, all 4
patients underwent replacement of the aortic
arch under deep hypothermic circulatory ar-
rest either with or without selective cerebral
perfusion, depending on the needs of each
case.
Administration of cardioplegic solution
was thus performed after the aorta was
transected under deep hypothermic arrest.
Therefore inability to administer cardiople-
gic solution was not an essential problem.
Repair of the apex was completed during
cardiac arrest, and systemic perfusion was
resumed through cannula in the graft.
We concur with Terada and Nakamura
regarding the usefulness of the axillary artery
as the first alternative access to the femoral
artery.3 We used axillary artery cannulation
in 23 of 935 patients who underwent cardiac
surgery with cardiopulmonary bypass. In the
4 patients who underwent transapical cannu-
lation, both the femoral artery and axillary
artery were inaccessible or inadequate as a
systemic perfusion site because of com-
pressed true lumen of the descending aorta,
severe obesity, or subclavian artery disease.
If a patient has these conditions, transapical
aortic cannulation is indicated. We believe
that transapical aortic cannulation is safe and
useful for such selected patients.
Ikuo Fukuda, MDa
Kozo Fukui, MDa
Ko Watanabe, MDb
Motoo Osaka, MDb
Department of Surgery 1
Hirosaki University School of Medicine
5 Zaifu-cho
Hirosaki, Aomori, 036-8562, Japana
Department of Cardiovascular Surgery
Tsukuba Medical Center
Tsukuba, Japanb
References
1. Fukuda I, Aikawa S, Imazuru T, Osaka M.
Transapical aortic cannulation for acute aor-
tic dissection with diffuse atherosclerosis.
J Thorac Cardiovasc Surg. 2002;123:369-
70.
2. Tanaka T, Kawamura T, Ohara K, Matsu-
moto M, Maeta H, Hiratsuka H. Transapical
aortic perfusion with a double-barreled can-
nula. Ann Thorac Surg. 1978;25:209-14.
3. Neri E, Massimo M, Capanini G, Carone E,
Tucci E, Diciolla F, et al. Axillary artery
cannulation in type A aortic dissection op-
erations. J Thorac Cardiovasc Surg. 1999;
118:324-9.
doi:10.1067/mtc.2003.256
Thymectomy in ocular myasthenia
gravis
To the Editor:
We read with interest the recent article by
Roberts and associates1 on thymectomy in
the treatment of ocular myasthenia gravis
(OMG). It represents an important step in
the debate concerning this issue and in the
consideration of OMG as part of a broad-
spectrum disease and not as a distinct dis-
ease.
What we know from the literature is
that the disease will progress in about 50%
of patients with initial OMG.2 On the other
hand, thymectomy is considered a main-
stay therapy for generalized myasthenia
gravis (GMG), and the best outcome is
expected in patients operated on early after
the onset of the disease.
What we should simply do is predict
when a pure OMG is an initial GMG and
offer to such patients the best treatment,
which might also include an extended
thymectomy.
Apart from the presence of a thymoma,
which makes the surgical procedure man-
datory, no clear indication for thymectomy
in OMG appears in the literature.
Only a few studies have focused on
thymectomy in OMG,1,3-5 and when pa-
tients with OMG are merged with those
with GMG, the assessment of the efficacy
of thymectomy is difficult for the combined
action of various medical therapies and for
the lack of standardized methods for as-
sessing patient status before and after sur-
gical intervention and assessing the correct
criteria of success.
A contribution to the discussion about
this topic might be derived from our expe-
rience.
From 1993 to now, 29 patients with
OMG underwent transternal extended
thymectomy at our institution. In the same
period, the same neurologist (R.R.) treated
343 patients with OMG, and consequently,
the eligibility rate for surgical treatment of
OMG was 8.5%.
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Specific indications for the operation
were as follows:
1. Presence of thymoma (n  20) or
suspected thymic mass (n  3) on
the thoracic computed tomographic
or nuclear magnetic resonance scan
2. High titers of acetylcholine receptor
antibody (n  3)
3. Resistance to pyridostigmine ther-
apy or relapse after steroid or immu-
nosuppressive therapy (n  1)
4. Dependance on a high dosage of cor-
ticosteroids (n  2).
Our mortality rate was nil, and no major
morbidity was experienced. That is com-
mon to most of the surgical teams skilled in
the treatment of myasthenic patients and
makes the thymectomy a generally consid-
ered safe procedure.
The neurologic results of thymectomy
in our overall series of 45 patients with
OMG have been recently reported.6 The
remission rate was significantly higher in
patients with stage I myasthenia than in
those in the other Osserman categories.
In the more recent series of 29 patients,
the neurologic postoperative results were
22 complete remissions, 3 remissions with
medication, 3 cases of improved status, and
1 case of unchanged status.
Our experience, general considerations,
and results suggest that extended thymec-
tomy might play a role in highly selected
patients with OMG, and there is need for
further studies to assess its efficacy.
We again congratulate the authors, who
have focused and debated on what is con-
sidered a highly controversial indication
for thymectomy.
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Reply to the Editor:
We appreciate the comments by Lucchi
and colleagues at the University of Pisa.
Their results are consistent with ours, but
they differ in one important respect. In their
group of 29 patients, 23 were operated on
because of thymomas or suspected thymic
masses, and 3 had thymectomies because
nonoperative therapy had been ineffective
or was not tolerated. This suggests that
only 3 of their 29 patients had thymecto-
mies specifically for the treatment of ocular
myasthenia gravis (OMG), whereas OMG
was the indication for operation in all of
our patients. Our findings, supported by
those of Lucchi and associates and the Uni-
versity of Pennsylvania group,1 strongly
suggest that thymectomy achieves greater
remission rates for OMG than for more
advanced forms of myasthenia gravis. Thus
we recommend operation as the primary
treatment for OMG when the diagnosis is
firm.
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Percutaneous valve insertion: A new
approach?
To the Editor:
The recently published article on percuta-
neous aortic valve replacement Lutter and
associates1 strengthens our belief that non-
surgical valve replacement will soon be-
come a reality in the replacement of semi-
lunar cardiac valves.
Andersen, Knudsen, and Hasenkam2 re-
ported a nonsurgical heart valve replace-
ment as early as 1992, and this was fol-
lowed by similar attempts by other groups.
Many technical problems have been en-
countered. The size of the vascular access
required was too big, the function of the
valve after compression and re-expansion
could be compromised, and finally the
newly implanted valve could obstruct the
coronary orifices in aortic implantations.
We reported our first experimental studies
in 2000 for percutaneous pulmonary valve
replacement and, after ethical approval, the
first human heart valve implantation was
performed by us in September 2000.3,4. In
parallel, we reported our first successful
aortic implantations in an experimental
setup without creating coronary obstruction
due to a newly designed stent with a two-
step deployment strategy.5 In April 2002,
the French newspapers reported the first
successful percutaneous implantation of an
aortic valve as an emergency procedure in
a 47-year-old man in cardiogenic shock.
This came as a result of an ongoing re-
search project by Alain Cribier in Rouen,
France.
The article by Lutter and associates re-
ports their experience with aortic implan-
tations. As in our early aortic work, they
have experimented with valve implanta-
tions in the supracoronary position. In this
position, the valve implant does not ob-
struct the coronary orifices and the pressure
difference over the closed valve is signifi-
cantly smaller. This decreases the force to
dislodge the valve after implantation and
leads to reduced stress on the functioning
valve leaflets. In our experience, implanta-
tion in this position was technically easy.
However, in contrast to Lutter and cowork-
ers, we had significant problems with cor-
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